Takeda To Buy IDM Pharma Of U.S., Maker Of Bone Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical said it intends to buy U.S. drug maker IDM Pharma for $66.7 million in cash. With the purchase, Takeda expects to get the American firm's Mepact (mifamurtide), a cancer drug for treating osteosarcoma. The drug has yet to be approved by the U.S. FDA, but it recently was cleared for marketing in Europe. Takeda's European CEO said the drug is capable of contributing in the near term to the firm's "top-line growth." (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.